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Slmvastatln inhibits PDGF-lnduced DNA synthesis in human glomeru-
lar mesanglal cells. Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme
A (HMGCoA) reductase ameliorate glomerular pathology and renal
dysfunction in different models of glomerular disease. This effect has
generally been attributed to a decrease in the circulating levels of
cholesterol. Focal or diffuse mesangial cell proliferation is a common
feature of glomerular pathology. There is now evidence from studies in
vitro and in vivo that platelet-derived growth factor (PDGF) is an
important mediator of glomerular hypercellularity. The activity of
HMGCoA reductase has previously been shown to be a requirement for
cell growth. In the present study, we examined the effect of simvastatin,
an HMGCoA reductase inhibitor, on PDGF-induced DNA synthesis
and PDGF B chain gene expression in human glomerular mesangial
cells. In addition, we investigated the effect of simvastatin on phospho-
lipase C (PLC) and protein kinase C (PKC) activation stimulated by
PDGF. We demonstrate that treatment of the cells with simvastatin
completely inhibits PDGF-induced DNA synthesis. This inhibition is
reversed by mevalonate but not by cholesterol or farnesol, two major
metabolites of the mevalonate pathway. On the other hand inhibition of
HMGCoA reductase does not influence PDGF-induced activation of
PLC and PKC, or PDGF B chain gene expression. These data suggest
that simvastatin acts at a late step in the PDGF mitogenic pathway
without interfering with other early cellular responses elicited by this
growth factor. These studies also raise the possibility that the amelio-
rative effect of HMGCoA reductase inhibitors on glomerular pathology
may be mediated, at least in part, by a direct cellular effect.
Progressive renal diseases, particularly those characterized
by severe proteinuria, are almost invariably associated with
elevated plasma levels of lipids [1, 2]. The associated hyper-
cholesterolemia has been incriminated as an aggravating factor
that accelerates the development of glomerulosclerosis [3].
Several studies in experimental animals with nephrotic syn-
drome or with various degrees of renal ablation have docu-
mented the deleterious effect of cholesterol feeding on renal and
specifically glomerular pathology [3]. Moreover, inhibitors of
3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reduc-
tase, the rate limiting enzyme in the cholesterol biosynthetic
pathway, ameliorate the structural and functional changes seen
in these models [4-6]. The beneficial effects of these cholesterol
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lowering drugs have generally been attributed to the decrease in
circulating levels of cholesterol. Certain forms of human as well
as experimental models of glomerular injury are characterized
by focal or diffuse mesangial cell proliferation [7]. Presently,
there is evidence that activation and proliferation of this popu-
lation of glomerular cells may represent an important step in the
development of diffuse glomeruloscierosis [8]. The precise
mechanisms that lead to mesangial cell proliferation are incom-
pletely understood. Platelet-derived growth factor (PDGF)
could play a key role in this context. PDGF is a potent mitogen
for mesangial cells in vitro [9] and there is evidence that this
growth factor and its receptor are upregulated in experimental
and human glomerular diseases [10—12]. Several recent obser-
vations suggest an important role for cholesterol or other
metabolites of the mevalonate pathway in the signal transduc-
tion mechanisms involved in cell transformation and growth
[13—15]. Inhibition of mevalonate production in cells treated
with HMGCoA reductase inhibitors [13, 15] or in mutant cells
lacking HMGCoA synthase [16] causes an arrest of the cell
cycle in G1 phase that is not overcome by cholesterol, suggest-
ing that intermediate(s) in this metabolic pathway may have a
central role in the regulation of the cell cycle. These observa-
tions raise the possibility that the effect on glomerular pathol-
ogy observed in response to these drugs may result, at least in
part, from a direct action at the cellular level. In our study, we
investigated the effect of an HMGCoA reductase inhibitor,
simvastatin, on DNA synthesis and autoinduction of PDGF B
chain gene expression in human glomerular mesangial cells
stimulated by PDGF. In addition we investigated the effect of
simvastatin on two early events in the PDGF signal transduc-
tion pathway, phospholipase C (PLC) and protein kinase C
(PKC) activation.
Methods
Cell culture and characterization
Normal human kidney tissue unsuitable for transplantation
was used to culture mesangial cells from outgrowths of colla-
genase-treated glomeruli. Mesangial cells were extensively
characterized by electron microscopy and immunohistochemi-
cal staining as previously described [9]. The cells were grown in
Waymouth's medium containing 17% fetal calf serum. In all the
experiments the cells were used between passages six and ten.
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Measurement of DNA synthesis
DNA synthesis was measured as the incorporation of [3H]-
thymidine into trichioroacetic acid (TCA) insoluble material.
Confluent mesangial cells in 24 well dishes were made quiescent
by placing them in serum free Waymouth's medium for 72
hours. For studying the effect of HMGCoA reductase inhibitor
simvastatin, the cells were preincubated with simvastatin or
vehicle dimethylsulfoxide at the indicated concentrations for 18
hours before the experiment. Human recombinant PDGF BB
(12 ng/ml) was then added to quadruplicate wells for 28 hours.
During the last four hours of the incubation period the cells
were pulsed with [3H]-thymidine (1 pCi/ml, New England
Nuclear, Boston, Massachusetts, USA). The medium was then
removed, the cells were washed twice in ice cold 5% TCA and
then incubated in 5% TCA on ice for five minutes. The cells
were solubilized by adding 0.7 ml of 0.25 N NaOH in 0.1%
sodium dodecyl sulfate (SDS). Half milliliter aliquots were then
neutralized and counted in scintillation fluid.
RNA isolation and solution hybridization assay
Human glomerular mesangial cells grown to confluence in 100
mm petri dishes were made quiescent by placing them in
serum-free Waymouth's medium for three days. The cells were
treated for the last 18 hours with simvastatin, then PDGF BB
(12 ng/rnl) was added. At the end of the incubation the cells
were lysed in guanidine isothiocyanate buffer at the indicated
time points. Sodium-N-laurylsarcosine to a final concentration
of 0.5% and 0.35 glml of cesium chloride (CsC1) were added and
the cell homogenates were layered on a 1.2 ml cushion of 5.7 M
CsCl, 0.1% EDTA and centrifuged for 18 hours at 100,000 x g
at 20°C. The supernatant was carefully discarded and the pellet
containing the RNA was resuspended in 5 m sodium citrate
buffer and extracted with chloroform/butanol. 0.3 M sodium
acetate followed by 2.5 volumes of absolute ethanol were added
and the RNA precipitated from the aqueous phase after centrif-
ugation was resuspended in sterile water, quantified by spec-
trophotometry and stored at —80°C. A ribonuclease protection
assay was used to determine PDGF B chain mRNA expression.
The cDNA template was constructed by cloning a 960 bp
Banil-Banil restriction fragment encompassing portion of ex-
ons 6 and 7 of the c-sis gene into the Sma! site of plasmid pT7-2.
To generate the single stranded 32P labeled RNA probe, the
plasmid was linearized and transcription was carried out using
T7 RNA polymerase (Promega) in the presence of 40 mM
Tris-HC1 pH 7.5, 6 mri MgCI2, 10 mr,t NaCI, 2 mi spermidine,
40 m dithiothreitoi, 40 U/mi RNasin, 0.5 m each of ATP,
GTP and CTP, 12 /.LM UTP and 50 sCi of 32P-UTP (800
Cilmmol, Amersham) at 37°C for one hour. This was followed
by the addition of RNase free DNase (Promega) and another 15
minutes incubation to digest the DNA template. After repeated
extraction with phenol chloroform and precipitation in ethanol,
the RNA pellet was resuspended in hybridization buffer con-
sisting of 80% formamide. The labeled RNA probe (1 x 106
cpm) was hybridized at 50° to 100 g of total RNA prepared
from mesangial cells. After hybridization the samples were
digested with RNase A (50 jsg/ml) and RNase T1 (2 sg/ml)
followed by the addition of proteinase K to inactivate the
remaining RNase. After extraction in phenollchlorophorm the
samples were precipitated in ethanol and redissolved in loading
buffer containing 90% formamide and separated on 6% poly-
acrylamide/urea gel. Gels were exposed to Kodak Xomat films
with intensifying screens at —70°C.
Phosphatidylinositol hydrolysis
Confluent mesangial cells in 12 well dishes were placed in
inositol free serum free RPM! 1640 containing 3 sCiIml of
2[3H]-myoinositol for 48 hours. In the last 18 hours, the cells
were treated with simvastatin at the indicated concentrations.
After a 15 minute preincubation with 15 m LiCI at 37°C,
PDGF BB (12 ng/ml) was added to triplicate wells, with or
without the HMGCoA reductase inhibitor, and incubated for
five minutes. The cells were harvested in 5% trichloroacetic
acid (TCA) and ether extracted to remove the TCA. The
samples were then loaded onto 2 ml AG1X8 anion exchange
columns (Biorad). The columns were washed with 10 ml of
water and 10 ml of 5 m sodium tetraborate. Inositol phos-
phates were eluted with 10 ml of 0.8 M ammonium formate in
0.1 M formic acid. Five milliliters of this fraction were mixed
with scintillation fluid and counted in a beta counter.
Protein kinase C assay
Confluent mesangial cells were made quiescent by placing
them in serum free medium for 48 hours. In the last 18 hours,
the cells were preincubated with simvastatin (10 ILM) and then
stimulated with PDGF BB (12 ng/ml) for 15 minutes. The cells
were washed twice with phosphate buffered saline and lysed in
homogenization buffer (20 mri Tris-HC1, pH 7.5, 0.5 mM
EDTA, 0.5 mii EGTA, 0.5% Triton Xl00, 25 sg/ml aprotinin,
25 g/ml leupeptin) at 4°C. The cell lysate was centrifuged at
10,000 x g for 30 minutes at 4°C. Protein kinase C was partially
purified using the DE-52 (DEAE) column. The protein concen-
tration in the eluate was measured by the Bio-Rad method.
Protein kinase C activity was determined by measuring phos-
photransferase activity to a synthetic peptide from myelin basic
protein in the presence of phorbol ester, phosphatidylserine and
32P labeled ATP. A pseudosubstrate inhibitor was used to
determine the nonspecific activity. Phosphotransferase activity
was expressed as pmoles of 32P incorporated into the synthetic
peptide/5 mm. Reagents used were from a commercial kit
(BRL).
Results
Effect of simvastatin on PDGF-induced DNA synthesis
First, we examined the effect of HMGCoA reductase inhibi-
tion on PDGF-induced DNA synthesis in human glomerular
mesangial cells. When the cells were pretreated with simvasta-
tin, PDGF-induced 3H-thymidine incorporation into DNA was
inhibited in a dose dependent manner (Fig. 1). The inhibitory
effect was already detectable at 1 M and was maximal at 10
LM. To exclude a toxic effect of simvastatin, cell viability was
checked by trypan blue exclusion. Under the same conditions
in which simvastatin completely inhibited DNA synthesis cell
viability was 94.9% + 3.3%. To demonstrate that the inhibition
of DNA synthesis was due to inhibition of the HMGCoA
reductase, we investigated the effect of simvastatin on DNA
synthesis in the presence of mevalonate. The ability of meva-
lonate to completely restore PDGF-induced DNA synthesis
(Fig. 2) indicates that the inhibitory effect is, indeed, related to
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Fig. 1. Effect of simvastatin on PDGF-induced DNA synthesis. Con-
fluent quiescent mesangial cells were pretreated with the indicated
concentrations of simvastatin for 18 hours before the addition of PDGF
(12 ng/mi). DNA synthesis was measured as the amount of PHI-
thymidine incorporated into tnchloroacetic acid insoluble material as
described in Methods. Data represent mean SEM of 5 separate
experiments, each done in quadruplicate wells. *f < 0.05 compared
with PDGF.
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Fig. 2. Effect of simvastatin and mevalonate on PDGF-induced DNA
synthesis. Confluent quiescent mesangial cells were preincubated with
simvastatin (5 zM)and the indicated concentration of mevalonate for 18
hours before the addition of PDGF (12 ng/ml). DNA synthesis was
measured as the amount of (3H]-thymidine incorporation into trichlo-
roacetic acid insoluble material as described in Methods. Data represent
mean SEM of three separate experiments each done in triplicate.
0.01 compared with PDGF, **D < 0.01 compared with PDGF +
simvastatin.
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Fig. 3. Effect of simvastatin and cholesterol on PDGF-induced DNA
synthesis. Confluent quiescent mesangial cells were preincubated with
simvastatin (5 pi) and cholesterol at the indicated concentration for 18
hours. The cells were then stimulated with PDGF (12 ng/ml) and DNA
synthesis was measured as incorporation of [3H1-thymidine into trichlo-
roacetic acid precipitable material as described in Methods. Data
represent mean SEM of four separate experiments each done in
quadruplicate. *f < 0.01 compared with PDGF.
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Fig. 4. Effect of simvastatin and farnesol on PDGF-induced DNA
synthesis. Confluent quiescent mesangial cells were pretreated with
simvastatin (5 sM) and farnesol at the indicated concentration for 18
hours. The cells were then stimulated with PDGF (12 ng/ml) and DNA
synthesis was measured as the amount of [3H]-thymidine incorporated
into trichloroacetic acid precipitable material as described in Methods.
Data represent mean SEM of three separate experiments each done in
quadruplicate. < 0.01 compared with PDGF.
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the inhibition of the mevalonic acid pathway. On the other hand
addition of cholesterol did not overcome the inhibition caused
by simvastatin as shown in Figure 3. We next examined if
famesol could reverse the inhibitory effect of simvastatin.
Farnesol is directly involved in protein isoprenylation and is the
precursor of all other nonsterol isoprenes including dolichol and
ubiquinone. The addition of 5 M Farnesol did not reverse the
effect of simvastatin (Fig. 4). Higher concentrations of farnesol
actually resulted in a reduction of 3H-thymidine uptake by the
cells (data not shown).
Effect of simvastatin on PDGF-induced PDGF B chain gene
expression
We have previously demonstrated that PDGF is a potent
inducer of PDGF B chain gene expression in mesangial cells [9].
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Fig. 6. Effect of simvastatin on PDGF-induced inositol phosphate
production. Confluent mesangial cells were incubated for 48 hours in
serum-free inositol-free RPMI 1640 and labeled with myo-23H-inositol
for the same period. The cells were pretreated with simvastatin (10 M)
for 18 hours. PDGF was then added to the cells for 10 minutes. Inositol
phosphates were extracted and analyzed as described in Methods. Data
represent mean SEM of six observations from two separate experi-
ments. < 0.01 compared with control.
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Fig. 5. Effect of simvastatin on PDGF-induced PDGF B chain mRNA.
Quiescent mesangial cells were preincubated for 18 hours with simvas-
tatin at the indicated concentrations. PDGF (12 ng/ml) was then added,
the cells were harvested after 3 hours and RNA was isolated as
described in Methods. One hundred micrograms of total RNA were
hybridized with a uniformly labeled c-sis RNA probe. Following
digestion with RNase A and Ti, the two protected fragments of 150 and
310 bp were electrophoresed on a denaturing polyacrylamide gel and
detected by autoradiography.
The induction of this gene is closely linked to mitogenesis since
growth factors that stimulate DNA synthesis in mesangial cells
also increase PDGF B chain mRNA levels [17]. We investigated
the effect of simvastatin on PDGF-induced PDGF B chain gene
expression. At concentrations that inhibited DNA synthesis,
simvastatin had no effect on the induction of PDGF B chain
mRNA (Fig. 5).
Effect of simvastatin on PLC and PKC activity
To determine if simvastatin interferes with early transmem-
brane signaling events in the PDGF mitogenic pathway, we
examined its effect on the activation of PLC and PKC induced
by PDGF. As shown in Figure 6, PLC activity measured as the
amount of intracellular inositol phosphates, is unaffected by
simvastatin. PKC activation in response to PDGF was also not
inhibited by simvastatin at concentrations that completely
inhibit DNA synthesis (Fig. 7). Therefore, inhibition of meval-
onate synthesis does not influence the early steps in PDGF
signalling pathways. The magnitude of PLC and PKC activation
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Fig. 7. Effect of simvastatin on PDGF-induced PKC activation. Qui-
escent confluent mesangial cells were pretreated with 10 sM simvastatin
for 18 hours and then stimulated with 12 nglml of PDGF BB for 15
minutes. The cells were then lysed and the PKC activity was measured
as described in Methods. Data represent mean SEM of six observa-
tions from two separate experiments. < 0.01 compared with control.
are similar in control cells and in cells treated with simvastatin
suggesting that this agent does not interfere with PDGF binding
to its receptor. Moreover, this observation excludes a toxic
effect of simvastatin on mesangial cells.
Discussion
In the present study, we demonstrate that treatment of
giomerular mesangial cells with simvastatin inhibits PDGF-
induced DNA synthesis in a dose dependent manner. This
inhibition can be reversed by the addition of mevalonate but not
cholesterol or farnesol suggesting the importance of other
product(s) of the mevalonate pathway in PDGF-induced DNA
synthesis. HMGCoA reductase inhibition had no effect on three
other events induced by PDGF: activation of PLC and PKC and
autoinduction of PDGF B chain mRNA. There have been
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conflicting reports regarding the necessity of HMGCoA reduc-
tase activity for PDGF-induced mitogenic response. While
Fairbanks, Witte and Goodman reported a close relationship
between the mevalonate pathway and mitogenesis in human
fibroblasts [13], Vincent, Walfert and Merler showed that the
mitogenic signalling pathway is unaffected by HMGCoA reduc-
tase inhibition [18]. The precise mechanisms by which the
mevalonate pathway influences cell growth are not yet com-
pletely clear and the eventual mediator has not been identified.
As we have demonstrated, cholesterol is not an absolute
requirement. Besides cholesterol there are other products of the
mevalonate pathway that are potential candidates for this role.
Ubiquinone and heme are terminal products of the mevalonate
pathway [19]. They are essential for mitochondrial respiratory
function, therefore the reduction of their intracellular concen-
tration may interfere with vital cell functions [19]. Moreover, it
has been demonstrated that the concentration of HMGCoA
reductase inhibitor that completely blocks cholesterol produc-
tion only slightly inhibits ubiquinone synthesis [19]. Dolichol,
another terminal product of the mevalonate pathway, plays a
key role in protein glycosylation [20]. Although exogenous
dolichol is ineffective in restoring growth of cells in which
mevalonate synthesis was blocked [151, biologically active
dolichol must be phosphorylated and this does not readily occur
when exogenous dolichol is added to cells in culture [20].
Besides dolichol, farnesyl and geranyl isoprenylated proteins
are other important candidates. One of the isoprenylated pro-
teins is the p21 ras the product of the ras oncogene [21]. Ras can
induce DNA synthesis as well as transient morphological trans-
formation when microinjected into quiescent cells [22, 23].
Farnesilation of the p2lras is an absolute requirement for its
transforming activity [14, 24]. In NIH 3T3 cells, microinjection
of anti-ras antibodies inhibits DNA synthesis induced by PDGF
[25]. Ras has been shown in different systems to induce
phosphatidyl inositol hydrolysis and PKC activation [26, 27].
Moreover, PKC activity plays an important role in mediating
the mitogenic effect of ras proteins [26, 28]. Our finding that
simvastatin did not interfere with PLC or PKC activation
suggests, albeit indirectly, that the effect of simvastatin is not
due to prevention of ras protein activation. The addition of
farnesol, the precursor of all nonsterol isoprenes, did not
reverse the effect of simvastatin on PDGF-induced DNA syn-
thesis. This observation contrasts with recent studies where
inhibition of serum-stimulated DNA synthesis by lovastatin in
mesangial cells isolated from Zucker rats was dependent on
farnesol [29]. This difference may be species specific or may be
due to the different agonists used bovine serum versus PDGF
since the small amount of PDGF present in bovine serum
cannot account for its mitogenic effect [30]. Since only phos-
phorylated farnesol can enter the pathway, it is conceivable that
exogenous farnesol can be phosphorylated by rat but not human
mesangial cells under the incubation conditions utilized in our
study. Other molecules that precede farnesol in the mevalonate
pathway may also be essential for PDGF-induced DNA synthe-
sis. One likely candidate is isopentenyl pyrophosphate. This
intermediate of the mevalonate pathway is the precursor for
isopentenyladenine. Previous studies have shown that isopen-
tenyladenine can effectively reverse DNA synthesis after
HMGCoA reductase inhibition [31, 32]. This compound is
essential for cells in late Gi to carry out S phase DNA
replication [32]. However, the addition of isopentenyladenenine
did not restore DNA synthesis inhibited by simvastatin (data
not shown). In rat mesangial cells, isopentenyladenine also did
not reverse the inhibitory effect of lovastatin on DNA synthesis
[30]. These findings do not exclude a role for other derivative(s)
or intermediates of the mevalonate pathway in mediating
PDGF-induced DNA synthesis. Regardless of the mechanism
by which the mevalonate pathway is involved in the regulation
of DNA synthesis, we demonstrate that it is not required for
other PDGF-induced cellular responses such as PLC and PKC
activation or PDGF B chain gene induction. These data suggest
that mevalonate starvation likely influences a late step in the
PDGF mitogenic pathway.
In summary, we have demonstrated a potential beneficial
effect of an HMGCoA reductase inhibitor on mesangial cells.
These in vitro studies suggest that some of the effects of
HMGCoA reductase inhibitors in vivo to ameliorate experimen-
tal glomerular injury could be mediated, at least in part, by a
direct effect on glomerular cells. The ameliorative effect of
lovastatin on mesangial cell proliferation without pronounced
reduction in serum cholesterol levels in a model of glomerulo-
sclerosis accelerated by dietary lipid supplementation supports
this hypothesis [33]. A recent study in human subjects with
hypertension and chronic renal failure demonstrated a superior
beneficial effect of combination therapy with simvastatin and
angiotensin converting enzyme inhibition over therapy with
angiotensin converting enzyme inhibition alone in preserving
renal function [34]. Further studies will be necessary to deter-
mine if HMGCoA inhibitors exert additional effects on target
cells besides inhibition of mitogenesis.
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